相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients
Yida Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
Melvyn T. Chow et al.
IMMUNITY (2019)
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy
Matteo Pallocca et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
Andre Kunert et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga et al.
GYNECOLOGIC ONCOLOGY (2019)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
E. E. Vokes et al.
ANNALS OF ONCOLOGY (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
Izak Faiena et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cemiplimab: First Global Approval
Anthony Markham et al.
DRUGS (2018)
Monoclonal antibodies in cancer immunotherapy
Ilgin Kimiz-Gebologlu et al.
MOLECULAR BIOLOGY REPORTS (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFkB activation
Jing-Bo Xia et al.
CYTOKINE (2016)
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma
S. Karakhanova et al.
BRITISH JOURNAL OF CANCER (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Interleukin-8 and Interleukin-17 for Cancer
Paul Zarogoulidis et al.
CANCER INVESTIGATION (2014)
Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
E. -M. Reitter et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Miguel F. Sanmamed et al.
CLINICAL CANCER RESEARCH (2014)
Cytokines and HCV-related autoimmune disorders
Alessandro Antonelli et al.
IMMUNOLOGIC RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion
Yue Wang et al.
CYTOKINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus
Ming-Fang Hsieh et al.
JOURNAL OF IMMUNOLOGY (2006)
High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma
T Kondo et al.
JOURNAL OF UROLOGY (2004)
分享论文
